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Abstract 
Presentation of Hodgkin lymphoma (HL) is distinctive in the infected individual being more 
advanced, accompanied by B symptoms and the presence of extranodal disease particularly 
lymphadenopathy of the head and neck. Bone marrow involvement may be found in over 50% of 
cases. Virtually all co express gamma-herpesvirus. Phenotypically there is prominence of the 
mixed-cellularity and lymphocyte depleted histopathologic subtypes that define an aggressive 
clinical course in comparison to other variants.  Prior to the induction of cART, median survival 
was only 1–2 years. Notably the first chemotherapy trial using ABVD (doxorubicin, bleomycin, 
vinblastine, and dacarbazine) in 21 patients, without treating the viral infection, resulted in a 
43% complete remission rate accompanied by severe haematological toxicities but did not extend 
median survival with this being 1.5 years matching the negative cases.   
Significant change accompanied concomitant anti-retroviral therapy that could be given safely 
even with dose intensive regimens exemplified by BEACOPP (bleomycin, etoposide, 
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) in 12 patients or the 
Stanford V regimen (doxorubicin, vinblastine, mechlorethamine, etoposide, vincristine, 
bleomycin, prednisone) coupled with involved-field radiation for bulky disease studied in 59 
patients. BEACOPP extended overall survival (OS) to 83% at 2 years. A similar trend was seen 
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when using the Stanford V regimen with an OS rate of 51% at 3 years, disease-free survival 
(DFS) of 68% and freedom from progression (FFP) in 60%. Additional benefits accrued from 
supportive care with stimulatory peptides such as G-CSF and when combined with bacterial 
prophylaxis results approached that found in the uninfected reference group.  Current consensus 
holds this particular lymphoma as still among the non-AIDS defining cancers being lung, 
stomach, liver or anal despite these having recently gained more attention as several of these 
neoplasms may be occurring more commonly in the era of cART.  
While the relative risk of developing a non-AIDS-defining neoplasm in HIV-infected persons on 
the average is 2–3 times, the risk for developing HL in HIV-infected cases impressively ranges 
between 5 and 25 times when compared to the general population. Based on the precedent in 
which Kaposi sarcoma and the non-Hodgkin lymphomas distinctively alter the course of this 
retroviral infection in a way indistinguishable from concurrent Hodgkin lymphoma we propose 




Acquired immunodeficiency syndrome (AIDS) in the wake of infection with human 
immunodeficiency virus (HIV) was firstly described in homosexual men living in Los Angeles 
[1]. This was followed by reports of a markedly higher risk of developing malignancies such as 
Kaposi’s sarcoma (KS) [2] and [3], primary cerebral and systemically occurring non-Hodgkin 
lymphoma (NHL) [4], [5], [6], [7] and [8] as well as invasive cervical cancer in those harbouring 
this virus, although the incidence of the latter malignancy has not increased as dramatically 
[9] and [10].  
With the introduction of combination anti-retroviral therapy (cART) in 1996 [11] a modification 
not only on the morbidity and mortality related to HIV disease but also the spectrum of the 
different malignancies reported in HIV-infected patients has occurred.  An increasing number of 
other neoplastic disorders including HL, testicular seminoma and lung cancer are still described 
as non-AIDS defining [12], [13] and [14]. Of note is a long-running Swiss study showing no 
increase in this particular lymphoma in recent years and also not among persons infected with 
the human immunodeficiency virus [15]. The same workers find no evidence of any increasing 
risk with improving immunity.  
In this context is the role played by concurrent gamma-herpesvirus coinfection [16]. This 
distinction may be artificial given that most infected individuals live in sub Saharan Africa 
(SSA) where no plateau has yet been reached for infection rates [17] with South Africa in the 
midst of a pandemic having 5.5 million people testing positive [18].  Here malignant disease 
contributes significantly to morbidity and mortality particularly in this community [19]. The 
opportunity has therefore been taken extending our previous observations on KS and NHL 
[20] and [21] to examine a similar possible association for HL. 
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2. Epidemiology 
Almost 20 years ago, Hessol and colleagues were the first researchers observing an excess 
number of Hodgkin cases among HIV-infected gay men associated with significantly worse 
outcome particularly higher mortality rates [22]. Cure rates for this lymphoma in the general 
population is expected to be in the range of 70–80% [23]. Thus a US based study carried out 
between 1988 and 1998 demonstrated a 5-year survival of 38% compared with 78% in negative 
matched cohorts [24]. Data from the United States or Europe contrasts with only few studies 
exploring the situation in the most affected regions.  
For example, in a South African survey from 2005, overall HIV prevalence among the adults 
was 20% for females and 12% for males [25]: the risk of developing KS, NHL and HL was, 
respectively, 50, 6 and 2-fold higher when compared to the negative population.  Despite this 
being the second most common cancer in Africa incidence remains small when in contrast to the 
5–25-fold risk observed in western populations [26], [27] and [28]. Even so, none of the other 
tumour types examined being oral, liver or stomach cancer, melanoma, leukaemias or sarcomas 
showed a similar increased risk [25]. Furthermore, only few studies have provided information 
on HIV-infected individuals before progressing to AIDS [26] and [29].   
This is important to note as the widespread use of cART since 1996 has not only led to dramatic 
improvements in immune status and prolonged survival among HIV-infected persons [30] but 
many may now never develop the overt syndrome. Nevertheless persons only marginally 
immunosuppressed may still be at excess risk of developing associated malignancies especially 
with extended survival. A recent study highlights the complex correlation altered immunity and 
cART in the face of HL [14]. The incidence of this lymphoma increased substantially following 
an AIDS diagnosis but also, somehow paradoxically, rose over time in association with the 
introduction of cART. Furthermore, the authors of the study conclude that, among people with 
this syndrome, the relationship between risk for neoplastic transformation and CD4 count is 
nonlinear [14].  
Confirmation is therefore provided for results from prior studies describing an increasing risk 
over time subsequent to an AIDS diagnosis [27] and further elevation associated with the 
introduction of specific drug therapy [26]. 
3. Immunbiology, histological subtype and viral coinfection 
The recognition of certain HIV related malignancies correlate with loss of immune control for 
latent infections with oncogenic viruses such as the human herpesvirus 8 (HHV 8) for KS or 
Epstein Barr virus (EBV) for selected NHL subtypes [31].  In HIV-infected HL patients EBV 
positivity can be found in almost all cases [24], [32] and [33], in contrast to the negative cohorts, 
in which this association has been observed in only 20–50% depending on histological subtype 
and age at diagnosis [34]. These findings were confirmed on molecular level by showing the 
presence of EBV-associated antigens as well as EBV-encoded RNA (EBER) and latent 
membrane protein-1 (LMP-1) [16] and [24].   
Interestingly in the latter cases all histologic subtypes, other than nodular sclerosing, followed a 
more aggressive course [35] supporting the concept that the presence of both viruses adversely 
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affected survival [24]. The mechanism is postulated to reflect the induction of oncogenesis via 
production of the oncoprotein called LMP-1 released during infection of the lymphocytes 
[24] and [32].  This might explain the more virulent clinical characteristics and the predominance 
of the less favourable histologic subtype being mixed cellularity and lymphocyte depleted 
variants. 
Immune reconstitution with cART is causing an increased risk for these tumours by shifting 
HIV-infected individuals to a level of immunosuppression associated with highest risk 
[27] and [28]. The Reed Sternberg (RS) cell seems to play a central role in facilitating such 
complex interactions. It was hypothesized that in severely immunosuppressed HIV-infected 
individuals usually presenting with CD4 counts below 50/μl these malignant giant cells cannot 
recruit lymphocytes and histiocytes, both usually known to produce proinflammatory cytokines, 
essential survival of this unique tumour cell.  
With the increase in CD4 counts during effective anti-retroviral therapy (immune reconstitution) 
it seems that an overshooting, perturbed and nonlinear way of immunosuppression is needed for 
the manifestation of disease [28].  Oncogenesis of other HIV related cancers such as cervical, 
anal or hepatic is associated with specific co-viral infections caused by the human 
papillomavirus (HPV), hepatitis B or C virus but since even though these neoplasms arise at 
increased frequency the importance of immunosuppression is less clear [36] and [37]. 
4. Clinical findings and presentation 
Hodgkin manifests more aggressively in the HIV-infected population. Bone marrow involvement 
has been documented in 40–60% at diagnosis, and may be the initial feature in about 20% of 
patients; therefore trephine biopsy should be obligatory [38].  An explanation could be that, in 
the setting of HIV infection, patients undergo this examination more often for the evaluation of 
obscure fever, night sweats, fatigue, weight loss as well as pancytopenia [39]. Atypical clinical 
presentations and unusual pathologic characteristics occur in 30–60% of HIV-negative 
individuals even with advanced stages of disease at diagnosis whereas then systemic symptoms 
are found in more than 70% once positive [39] and [40].   
Furthermore, Poluri et al. [41] noted 100% of the HIV cases the involvement of head and neck 
regions in patients compared to 81% of non-HIV cohorts. Similarly 80% of cases had stage III 
and IV HD compared to 45% of the reference population. Also 75% had mixed cellularity 
subtype in contrast to 50% uninfected individuals.  The swollen lymph nodes can get very large 
and the fever shows a characteristic rise and fall described as Pel-Ebstein, very often 
accompanied by anaemia and fatigue. 
5. Diagnosis and staging 
Lymph node or tissue biopsy of suspected lesions to confirm presence of the characteristic Reed-
Sternberg cells is routine but should be always accompanied by bone marrow biopsy due to the 
high likelihood of involvement in patients.  In order to minimize late effects without 
compromising efficacy, risk-adapted strategies, based not only on pre-treatment prognostic 
factors but also on the results of early restaging positron emission tomography (PET) scans have 
been recently developed [42].   
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Despite the superiority of the functional imaging, computed tomographic (CT) scans are still 
routinely used in the initial staging of HL. The reason for this anomaly could be that, although 
the former is preferred with an advantage in detecting lymphomatous lesions in a further 
approximately 15%, this “upstaging” effect will not result in a change of treatment strategies 
based on standard chemotherapy protocols as first-line treatment.  
However, the role of more sensitive techniques has become more important in the restaging 
process after initiation of treatment where it was shown to influence prognosis and treatment 
outcome [43], [44], [45] and [46].  Although it is widely accepted that a positive interim PET 
reflects poor prognosis, it is yet unknown whether a change of therapy in these patients will 
result in improved survival. Also the false positive results await better understanding. 
6. Treatment 
6.1. Limited 
Defined as having nodal disease, with or without minimal local extension into nearby tissues, on 
one side of the diaphragm (Ann Arbor stage I or II), absence of B symptoms, no single tumour 
mass greater than 10 cm in largest diameter and normal ESR.  Three groups have reported the 
results based on the use of brief exposure to ABVD followed by irradiation for clinical stage IA 
or IIA non-bulky HL [47], [48] and [49]. The results from these studies favour this approach in 
minimising the risks for later infertility, premature menopause, leukaemia as well as 
cardiopulmonary toxicity [50] and [51].  
Further reduction in sequelae is possible by avoiding radiotherapy.  This step is based on the 
National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology 
Group [52] trial comparing ABVD alone with either wide-field radiation for patients with 
favourable prognostic factors or two cycles followed by similar radiotherapy for those in the 
category with modest but statistically significant difference in progression-free survival in favour 
of combined modality therapy but no difference in overall survival.  
Therefore such a regimen is currently regarded as an acceptable option for these cases in contrast 
to bulky early stage disease where additional irradiation remains the standard of care. 
6.2. Advanced 
Here chemotherapy alone has emerged as optimum [50] and [51]. Specifically protocol ABVD 
given on schedule, without delay and no growth factor support regardless of the absolute 
neutrophil count on the day of treatment, is advocated. Of note, however, is the use of 
stimulatory peptide increases bleomycin induced lung toxicity [53] and [54].  Alternatives are 
Stanford V and escalated BEACOPP [55] and [56] where encouraging results are offset by a 
marked increase in both short- and long-term toxicities, including infertility, infectious 
complications and second malignancies so that there is a relevance to use BEACOPP routinely.  
However, it does represent a reasonable alternative particularly with high-risk disease as defined 
by the International Prognostic Score (IPS) [56] and [57].  Despite the CD20 negative 
immunophenotype in most of the cases several investigators have studied the role of rituximab in 
the treatment of classical variants. The basis includes direct killing of the Reed-Sternberg cells in 
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the 15% of these cases, depleting B cells in the microenvironment that may be necessary for 
tumour cell survival and the possibility that these may identify a postulated Hodgkin stem cell 
[58] and [59].   
In the light of evolving experience are trials testing the impact of positivity on the interim PET 
CT scan in which early inclusion of BEACOPP or ICE containing ifosfamide, carboplatin, 
etoposide, with or without the use of stem cell transplantation, are attractive but there is currently 
no proof that this will improve outcome. 
6.3. Relapse 
Recurrence reduces long-term disease-free survival with standard dose chemotherapy to below 
20% [60] and [61]. Exception exists in two subgroups. Firstly those who recur exclusively in the 
originally involved but unirradiated lymph nodes without B symptoms or extranodal disease 
[62] and [63] and here wide-field irradiation with or without additional chemotherapy may cure 
approximately 50% of patients [63] and [64].  Secondly when this occurs more than 1 year after 
remission and in the absence of constitutional symptoms repeating the same regimen or using 
potentially non-cross-resistant chemotherapy with or without irradiation eradicates disease in 
approximately 35% of the relapsed patients [60], [65] and [66].  
However, both subgroups could be alternatively considered for autologous stem cell 
transplantation (ASCT).  Immunomodulatory agents such as thalidomide or lenalidomide are 
generally well tolerated and thought to alter the inflammatory environment surrounding the 
Reed-Sternberg cells or by blocking angiogenesis. Thalidomide, in combination with vinblastine, 
had a response rate of 36% in a phase II study of heavily pre-treated patients with Hodgkin 
lymphoma [67].  Rituximab has documented activity in previously untreated and relapsed 
lymphocyte predominant Hodgkin lymphoma was shown by the GHSG [68].  
In relapse 15 patients treated with four weekly doses of rituximab to achieve a response rate of 
94% with a median time-to-progression of 33 months and a 7-year overall survival of 93%.  The 
results of two randomised trials led to the establishment of autologous stem cell transplantation 
as the standard of care for relapses [69]. Presently no survival benefit could be established when 
employed in first or second relapse so favouring early use to minimize drug exposure and 
toxicity of previous salvage regimens.  
Furthermore, such timing decreases the chance of an inadequate stem cell harvest. 
Approximately 50% with chemosensitive relapse, defined as a partial remission or complete 
remission to salvage therapy, will have a durable remission following this intervention as 
compared to 20% with stable disease or a minor response to salvage chemotherapy [69], 
[70] and [71].  To date no randomised trials have compared the effectiveness of salvage 
regimens.  Thus etoposide with high-dose cytarabine and cisplatinum – ESHAP, ICE, mini-
BCNU or etoposide, cytosine arabinoside, and melphalan – BEAM, have been used. Recently 
gemcitabine-containing regimens have shown high response rates with an acceptable side-effect 
profile [72] and [73]. 
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6.4. Long-term complications 
Over time survival following treatment for Hodgkin’s lymphoma has improved significantly 
[74], [75], [76] and [77] as a consequence of multiagent chemotherapy strategies, more accurate 
radiotherapy modalities as well as better inclusive management. This is offset by increased risk 
for developing second primary cancers, infections and cardiovascular disease [78], [79], 
[80] and [81].  The main cause of death remains disease itself but after 20 years this is negligible 
[82]. In contrast the relative risks from second primary cancers and cardiovascular disease 
continue to increase after 10 years.  
More than 30 years following diagnosis this pattern is evident especially in those patients treated 
before the age of 21 but these risks seemed to decrease with age.  Emergence of secondary acute 
leukaemia is strongly associated with the use of alkylating chemotherapy as well as 
mechlorethamine, which is one component of the MOPP regimen [50]. Since these regimens, 
having poor survival [79] and [83], are less used there has been fall in the incidence of this late 
effect [83] and [84].  Splenectomy did not show any increased risk of death arising from 
infections. One explanation could be that this is due to vaccination against pneumococcal 
infections usually administered before or immediately after this operation. Instructions on the 
correct use of antibiotic prophylaxis and treatment are accordingly strongly recommended.  
Conversely protracted immunosuppression has been noted after splenectomy combined with 
radiotherapy and chemotherapy [85] and [86].  Smoking should be discontinued since it was 
shown to act synergistically with irradiation in the development of lung cancers and 
cardiovascular disease [87]. Especially in patients who received mediastinal radiotherapy 
screening for coronary artery disease, beginning 5 years after therapy, is recommended. Standard 
management of other risk factors including those for premature vascular disease, hypertension or 
lipid control may help to reduce this absolute excess risk. 
6.5. Management during pregnancy 
Since the vast majority of patients are treated with chemotherapy it is mandatory that staging of a 
pregnant patient should, besides necessary imaging, consist of a thorough history, physical 
examination, routine blood tests and a bone marrow biopsy.  Examinations such as 
ultrasonography, chest X-rays with proper shielding or magnetic resonance imaging should 
provide the desired diagnostic information without increasing the risk of foetal malformation 
[88] and [89]. Abdominal or pelvic CT are safest avoided during pregnancy giving higher foetal 
radiation exposure of up to 0.02 Gy.   
Positron emission tomography is increasingly favoured in staging. Since 18F-FDG or 
radioglucose can cross the placenta and reach the foetus, it may involve higher radiation 
exposure than regular CT and its use can therefore not be recommended in this context [90]. 
However, it can be performed after delivery to assess treatment response with the caveat that 
breastfeeding should be discontinued for at least 24 h because this isotope is concentrated both in 
the breasts and milk [91].  Many cytotoxic agents cross the human placenta and reach the foetus 
[92] due to their relatively low molecular weight.  
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When treating with chemotherapy the physiological changes occurring during pregnancy such as 
the renal clearance of drugs or increased plasma volume must be considered [93]. These changes 
might decrease the level of active drug concentrations [93].  Exposure in the first trimester has 
been associated with a 20% risk of developing major malformations [92] with this risk being 
lower with single agents compared to combination regimens accordingly [94] and [95]. If 
unavoidable in this period, abortion should be considered.  
Should termination be unacceptable, for religious reasons, one approach is to initiate single-agent 
anthracycline or vinca-alkaloid followed by combinations at start of second trimester. A further 
consideration is that alkylating agents may be less teratogenic than antimetabolites, which are 
considered to be the most injurious of all cytotoxic drugs used [92], [94] and [95].  There is some 
evidence suggesting that the ABVD combining adriamycin, bleomycin, vinblastine, dacarbazine 
is safe during pregnancy [93] and [96] as based on case reports. There is only limited experience 
regarding effects of MOPP [97] and none with the Stanford V or BEACOPP used in high-risk 
individuals.   
Thus upon diagnosis induction should be initiated promptly with thought given to therapeutic 
abortion acknowledging potential teratogenic effects in the first trimester as treatment delay has 
shown to adversely affect survival [98]. Thereafter such intervention is usually not associated 
with malformations but has shown to increases the risk of foetal or neonatal death, pre-term 
delivery and low birth weight [92] and [99]. Women can be safely treated comparably to their 
non-pregnant counterparts [92], [93] and [96] with full doses given [92], [96] and [98].   
Exposure to radiotherapy also needs consideration based on size of radiation fields and target 
dose. Since the most common presentation is supra-diaphragmatic lymphadenopathy, irradiation 
is feasible in early stage having isolated involvement of neck or axillary lymph nodes [100]. This 
modality in later gestation correlates with a carcinogenic effect and increased risk for 
leukaemogenesis or solid tumours within the first decade of life [101].  So far no teratogenic 
effects have been proven when granulocyte colony-stimulating factor or erythropoietin was 
needed to overcome treatment related cytopenia [102]. 
6.6. The cART era 
Before the introduction of these regimens, median survival of HIV-HL patients was 1.5 years 
[103] and [104] and so, very clearly, effective intervention is statistically of significant benefit.  
While the incidence of HIV-HL has increased concurrently with these therapies outcome been 
improved dramatically, particularly in cases treated concomitantly with chemotherapy and anti-
retroviral agents [34], [105], [106] and [107]. For example in a study by Gerard et al. [107] a 
significant increase in disease-free survival of 78% compared to 61% could be demonstrated.  
Similarly in 57 HIV-related HL patients the impact of cART on outcome was tested on survival 
to different anti-lymphoma schedules [106]. Those who responded by increasing CD4 cell count 
of 100/ul or a RNA level below 500 copies/ml had an overall survival rate of 89% at 2 years 
compared with 44% for those who did not meet this criterion or were over 45 years of age [106].  
Interestingly, limited data on the treatment with ABVD combined with cART in HIV-related 
HL, the standard in the non-immunosuppressed population, are available [106], [108] and [109].  
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For example the Spanish GESIDA/GELCAB Group [108] analysed outcome in advanced stage 
where 87% achieved CR: at median follow-up of 39 and 47 months, 5-year EFS and OS 
probabilities were 71% and 76%, respectively. An immunological response was observed in 56% 
and this was also virological in 68% of all treated patients leading to the conclusion that this 
regimen is effective and tolerated well.  Also that immunosuppressed people should be treated 
like immunocompetent patients assume adequate support and infectious prophylaxis in the 
former. One possible explanation for the favourable impact on response and survival to cART is 
that control of viral replication might decrease the continuous activation of the lymphoid system, 
which is one of the features involved in AIDS-related lymphomagenesis [110].   
Since the introduction of cART, commonly used chemotherapy regimens such as BEACOPP 
[111], Standford V [112] or VEBEP [113] given concurrently, have yielded encouraging results 
and all have proven to be feasible and highly effective in this interesting category of lymphoma. 
When using BEACOPP an overall survival of 83% was seen at 2 years. With the Standford V 
regimen 3-year OS, disease-free survival and freedom from progression being 51%, 68% and 
60%, respectively. Although 69% of patients were able to complete the treatment without 
compromising dose intensity grade 3 or 4 neutropenia occurred in 78% despite the use of G-CSF 
and some neurotoxicity was noted.   
In a separate analysis [114] based on the International Prognostic Score originally developed for 
Hodgkins [115] it was found that patients with high scores of greater than 2 treated with the 
Standford V regimen did significantly worse showing a complete response (CR) of 67% 
compared to those with scores below 2 where CR was 100%. Also overall survivals were, 
respectively, 33% compared to 76% at 3 years thereby emphasising the favourable predictive 
value of low scores less than two.   
The VEBEP made up of Vinorelbine, Epirubicin, Bleomycin, Cyclophosphamide and Prednisone 
study [113], demonstrated a high 75% complete remission, low relapse rate of 10% and 
outstanding overall and disease-free survival probabilities, respectively, of 86% and 90% at 
2 years on the background of acceptable and moderate toxicity.  The BEACOPP regimen so 
strongly advocated by the German Hodgkin Study Group seems to be highly effective but at the 
cost of some increased toxicity [111]. In a study of 12 patients only five received concomitant 
anti-retroviral therapy.  
After the completion of six cycles of this regimen nine patients have remained in CR after a 
follow up period of 49 months but three patients died within the study period. Two of 
opportunistic infections during treatment and one to relapse after 2 years. The most commonly 
observed toxicity was bone marrow suppression as grade 3–4 neutropenia in 75% of the cohort. 
Notably plasma levels of retroviral copies increased only moderately or even declined during 
chemotherapy if cART was given concomitantly.   
In a randomised trial full or dose-reduced schedules of epirubicin, bleomycin and vinblastine, 
together with zidovudine given from the beginning of therapy or started after the third cycle 
[116], gave an overall survival comparable for both arms but with the rate of opportunistic 
infection significantly lower in the dose-reduced treatment group. In a prospective non-
randomised trial adding prednisone to EBV to this regimen with zidovudine or dideoxinosyne as 
anti-retroviral treatment together with G-CSF 74% of the patients achieved CR. Unfortunately 
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the relapse rate was 38% and median survival was 16 months, with overall survival probability 
of 32% and disease-free survival at 53% at 36 months [117].   
The optimal chemotherapy for this viral – lymphoproliferative complex has yet to be defined. 
Despite the success achieved with the concomitant use of cART, there are also downsides, 
including drug-related adverse events and the development of resistance [118]. This has led to 
the view that therapy is best delayed until the CD4 cell count drops below 350/μl [119]. 
Significant complications of HIV infection usually occur when the CD4 cell count declines to 
less than 200/μl thus giving rise to the development of opportunistic infections [120].   
Newer anti-retroviral regimens with more favourable toxicity and resistance profiles than prior 
regimens have led to the suggestion of initiating therapy at higher CD4 cell counts [121]. 
Another important question that needs to be determined is whether earlier introduction directed 
against the retrovirus at a CD4 cell count above 350/ul would prevent Hodgkin lymphoma is 
currently unclear. The strong association between these tumours and EBV infection in HIV-
positive individuals [24], [32], [33] and [35] suggests that maintenance of higher CD4 counts 
might suppress the formation of EBV-containing malignant Hodgkin Reed-Sternberg cells.   
There are several questions that should be addressed in the future. Up to date, there have been no 
prospective longitudinal studies assessing the optimal CD4 count at which initiation of therapy 
would be most beneficial. Furthermore, against this background of treatment outcome shown 
over the previous years the question arises whether Hodgkin lymphoma should now be elevated 
to the status of an AIDS-defining entity similar to certain other lymphomas and Kaposi sarcoma. 
7. Concluding comments 
Whereas the incidence of AIDS-related neoplasms have decreased over time, others tumours, 
referred to as non-AIDS-defining malignancies such as Hodgkin lymphoma (HL), invasive anal 
carcinoma, cancer of lung or skin have emerged thus challenging HIV-treating clinicians and 
including all subspecialties. With the introduction of cART over the past decade the focus was 
predominantly on AIDS related malignancies resulting in a reduction of incidence for Kaposi’s 
sarcoma and non-Hodgkin lymphoma but neglecting certain tumours currently summarized as 
non-AIDS defining.  
In the upcoming years research might profitably focus on some of these non-AIDS defining 
entities and especially HL which has up to date not been considered as meeting such criteria.  
Although there is conflicting literature some more recent studies suggest that retrovirally infected 
individuals are at higher risk for a variety of cancers independent from their CD4 count. There is 
meanwhile a considerable amount of data demonstrating that the immunosuppression associated 
with this agent places infected individuals at higher risk for developing lymphomas, Kaposi 
sarcoma, and cervical cancer.  
Some data [30] and [122] suggests that non-AIDS-defining cancers are not associated with a low 
CD4 count per se and other factors, in combination with presence of the human 
immunodeficiency virus, such as coinfection with oncogenic agents (HHV8, EBV, HPV), 
lifestyle or advanced aging may be significant and seem to contribute to the increased risk for a 
range of neoplasms in this population.   
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This applies especially to HL occurring with a significantly, similar to AIDS related cancers, 
increased risk in HIV-infected individuals when compared with the general population. Specific 
therapeutic recommendations are lacking for these newly emerging malignancies including this 
particular lymphoma as well as others non-AIDS defining entities.  One of the many urgent 
questions to be addressed in future is when should therapy be started and, if it was initiated 
sooner, would the effects decrease the risk of developing non-AIDS-defining malignancies or 
have an effect on their course?  
There is substantial interest to re-evaluate the criteria for best time to first give these drugs on the 
background of publications. A few studies suggest that maintaining a higher CD4 count and 
lower HIV RNA level may have some protective effect on non-AIDS-defining cancer. However, 
there is more and more evidence that with rising CD4 counts the incidence of HL increases in 
HIV-infected patients whereas the incidence of NHLs decreases.  Only few reports have 
documented the protective effects of anti-retroviral therapy in non-AIDS-defining cancers and no 
prospective studies have been yet performed.  
The only one has so far showed that these were protective and that predictors for the 
development of apparently unrelated cancers were longer duration of the infection as well as a 
history of opportunistic events [30]. Interestingly CD4 count below 200/ul at the time of 
diagnosis was not associated with an increased risk for these entities, suggesting that factors 
other than a low CD4 cell count may be playing a role in the onset of cancer. In addition, patients 
not receiving medication or demonstrating higher viral copies were at greater risk for these 
cancers in general [30].  
In contrast, another large linked population based study [122] has shown that other than Hodgkin 
disease, lung cancer, and testicular seminoma, neoplasms were not strongly associated with the 
development of immunosuppression.  In patients with advanced stage Hodgkin in this setting, 
treatment with ABVD together with cART is feasible and effective. This supports the concept 
that patients where the lymphoma is present with virus should be similarly treated as 
immunocompetent cases presuming only that adequate supportive therapy and anti-infectious 
prophylaxis are given concomitantly.   
Several important questions remain to be clarified in the future. Protocols and clinical trials 
should focus on certain non-AIDS defining malignancies such as HL which share many common 
features with the AIDS defining entities. This specific lymphoma could arguably now be 
considered as AIDS defining with the important caveat that research focus in the future be on 
how to improve survival and treatment outcome. 
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